NASDAQ:PACB - Pacific Biosciences Stock Price, Price Target & More

Pacific Biosciences trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences (NASDAQ:PACB) released its earnings results on Thursday, February, 1st. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $24.94 million for the quarter, compared to analysts' expectations of $21.89 million. Pacific Biosciences had a negative return on equity of 98.98% and a negative net margin of 98.63%. The company's quarterly revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.21) earnings per share. View Pacific Biosciences' Earnings History.

Pacific Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Pacific Biosciences.

3 brokerages have issued twelve-month target prices for Pacific Biosciences' stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Pacific Biosciences' share price to reach $6.2667 in the next twelve months. View Analyst Ratings for Pacific Biosciences.

Pacific Biosciences saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 10,469,372 shares, a decrease of 19.4% from the March 15th total of 12,986,469 shares. Based on an average trading volume of 1,118,752 shares, the short-interest ratio is presently 9.4 days. Approximately 9.0% of the shares of the company are sold short.

Some companies that are related to Pacific Biosciences include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), pSivida (EYPT), Aethlon Medical (AEMD), Arrayit (ARYC), Precipio (PRPO), Pressure BioSciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).

Media coverage about PACB stock has trended positive on Thursday, according to Accern Sentiment. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pacific Biosciences earned a daily sentiment score of 0.39 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.17 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $2.54.

Pacific Biosciences has a market capitalization of $336.27 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences employs 456 workers across the globe.

Pacific Biosciences' mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]